HUP0400587A2 - Izoindolin-1-on glükokináz aktivátorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Izoindolin-1-on glükokináz aktivátorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0400587A2 HUP0400587A2 HU0400587A HUP0400587A HUP0400587A2 HU P0400587 A2 HUP0400587 A2 HU P0400587A2 HU 0400587 A HU0400587 A HU 0400587A HU P0400587 A HUP0400587 A HU P0400587A HU P0400587 A2 HUP0400587 A2 HU P0400587A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- ring
- substituted
- carbon atom
- carbon atoms
- Prior art date
Links
- 102000030595 Glucokinase Human genes 0.000 title abstract 2
- 108010021582 Glucokinase Proteins 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- -1 hydroxy- Chemical class 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical class CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Az (I) általános képletű, izoindolil-I-on-csoporttal helyettesítettpropionamidok az inzulinkiválasztást fokozó glükokináz aktivátorok,amelyek II típusú diabétesz kezelésére alkalmazhatók. A képletben Ajelentése helyettesítetlen fenilcsoport, vagy halogénnel egyszeresenvagy kétszeresen helyettesített fenilcsoport, vagy kis szénatomszámúalkilszulfonil-, kis szénatomszámú alkil-tio- vagy nitrocsoporttalegyszeresen helyettesített fenilcsoport; R1 jelentése 3-9 szénatomoscikloalkilcsoport vagy 2-4 szénatomos kis szénatomszámú alkilcsoport;R2 jelentése az aminocsoporthoz egy gyűrű-szénatomon keresztülkapcsolódó helyettesítetlen vagy egyszeresen helyettesített 5- vagy 6-tagú heteroaromás gyűrű, amely egy-három kén-, oxigén- vagy nitrogén-heteroatomot tartalmaz, mimellett az egyik heteroatom a kapcsolódógyűrű-szénatommal szomszédos nitrogénatom; amely heteroaromás gyűrűmonociklikus vagy két gyűrű szénatomjával fenilgyűrűvel kondenzálvalehet; mimellett az egyszeresen helyettesített heteroaromás gyűrű akapcsolódó szénatommal szomszédos szénatomtól eltérő valamelyhelyzetben valamely alábbi szubsztituenssel egyszeresen helyettesítvevan: halogénatom, kis szénatomszámú alkil-, nitro-, ciano-, perfluor-kis szénatomszámú alkilcsoport; hidroxi-, -(CH2)n-OR3, -(CH2)n C(O)-OR3, -(CH2)n C(O)-NH-R3, -C(O)C(O)-OR3 vagy -(CH2)n NHR3 csoport;mimellett R3 jelentése hidrogénatom vagy kis szénatomszámúalkilcsoport; és n értéke 0, 1, 2, 3 vagy 4. A találmány kiterjed avegyületek előállítására és ezeket tartalmazó gyógyszerkészítményekreis. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25527300P | 2000-12-13 | 2000-12-13 | |
| US31871501P | 2001-09-13 | 2001-09-13 | |
| PCT/EP2001/014404 WO2002048106A2 (en) | 2000-12-13 | 2001-12-07 | Isoindolin-1-one glucokinase activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0400587A2 true HUP0400587A2 (hu) | 2004-06-28 |
| HUP0400587A3 HUP0400587A3 (en) | 2011-03-28 |
Family
ID=26944583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0400587A HUP0400587A3 (en) | 2000-12-13 | 2001-12-07 | Isoindolin-1-one glucokinase activators, process for their preparation and pharmaceutical compositions containing them |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6482951B2 (hu) |
| EP (1) | EP1349856B1 (hu) |
| JP (1) | JP4021766B2 (hu) |
| KR (1) | KR100520651B1 (hu) |
| CN (1) | CN1247574C (hu) |
| AT (1) | ATE297922T1 (hu) |
| AU (2) | AU3841502A (hu) |
| BG (1) | BG107903A (hu) |
| BR (1) | BR0116169A (hu) |
| CA (1) | CA2430579C (hu) |
| CY (1) | CY1105587T1 (hu) |
| CZ (1) | CZ20031882A3 (hu) |
| DE (1) | DE60111570T2 (hu) |
| DK (1) | DK1349856T3 (hu) |
| EG (1) | EG24358A (hu) |
| ES (1) | ES2243578T3 (hu) |
| HK (1) | HK1063314A1 (hu) |
| HR (1) | HRP20030450B1 (hu) |
| HU (1) | HUP0400587A3 (hu) |
| IL (2) | IL156264A0 (hu) |
| MA (1) | MA26973A1 (hu) |
| MX (1) | MXPA03005170A (hu) |
| MY (1) | MY136741A (hu) |
| NO (1) | NO325810B1 (hu) |
| NZ (1) | NZ526236A (hu) |
| PA (1) | PA8534601A1 (hu) |
| PE (1) | PE20020593A1 (hu) |
| PL (1) | PL366006A1 (hu) |
| PT (1) | PT1349856E (hu) |
| RS (1) | RS50933B (hu) |
| RU (1) | RU2249590C2 (hu) |
| SI (1) | SI1349856T1 (hu) |
| SK (1) | SK8732003A3 (hu) |
| TW (1) | TWI294876B (hu) |
| UY (1) | UY27069A1 (hu) |
| WO (1) | WO2002048106A2 (hu) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| DE60316709T2 (de) | 2002-10-03 | 2008-07-17 | F. Hoffmann-La Roche Ag | Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren |
| AU2003302279B2 (en) | 2002-10-03 | 2008-06-12 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of Type 2 diabetes |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
| WO2004072066A1 (en) * | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| CN1960995B (zh) | 2004-04-02 | 2010-12-08 | 诺瓦提斯公司 | 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物 |
| RU2006138426A (ru) * | 2004-04-02 | 2008-05-10 | Новартис АГ (CH) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой |
| CA2621227A1 (en) * | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| JP2009513711A (ja) * | 2005-11-01 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン |
| JP2009513704A (ja) * | 2005-11-01 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン |
| CN101321747A (zh) * | 2005-11-01 | 2008-12-10 | 詹森药业有限公司 | 作为葡萄糖激酶变构调节剂的取代的环烷基吡咯酮类 |
| EP1951706A1 (en) | 2005-11-01 | 2008-08-06 | Janssen Pharmaceutica N.V. | Dihydroisoindolones as allosteric modulators of glucokinase |
| JP2009514835A (ja) * | 2005-11-03 | 2009-04-09 | プロシディオン・リミテッド | トリシクロ置換型アミド |
| JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| WO2007104034A2 (en) * | 2006-03-08 | 2007-09-13 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| ATE522518T1 (de) * | 2006-05-31 | 2011-09-15 | Takeda San Diego Inc | Indazol- und isoindolderivate als glucokinaseaktivierende stoffe |
| WO2008074694A1 (en) * | 2006-12-20 | 2008-06-26 | F. Hoffmann-La Roche Ag | Crystallization of glucokinase activators |
| EP2091947A2 (en) * | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| US8034819B2 (en) | 2007-03-07 | 2011-10-11 | Kyorin Pharmaceutical Co., Ltd. | Glucokinase activator |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20091313A1 (es) * | 2008-01-15 | 2009-09-03 | Lilly Co Eli | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina |
| WO2009092432A1 (en) * | 2008-01-24 | 2009-07-30 | Merck Patent Gmbh | Beta-amino acid derivatives for treatment of diabetes |
| PL2275414T3 (pl) | 2008-04-28 | 2016-01-29 | Kyorin Seiyaku Kk | Pochodne cyklopentyloakryloamidu |
| WO2009140624A2 (en) | 2008-05-16 | 2009-11-19 | Takeda San Diego, Inc. | Glucokinase activators |
| CN102216276A (zh) * | 2008-09-11 | 2011-10-12 | 辉瑞大药厂 | 取代的杂芳基物 |
| CN105176930B (zh) | 2010-03-31 | 2021-05-04 | 斯克里普斯研究所 | 重编程细胞 |
| US8178689B2 (en) * | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| JP6251038B2 (ja) | 2011-03-01 | 2017-12-20 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃアゴニストの調製方法 |
| US8470866B2 (en) * | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
| RS59663B1 (sr) * | 2013-05-27 | 2020-01-31 | Hoffmann La Roche | Nova jedinjenja 3,4-dihidro-2h-izokinolin-1-on i 2,3-dihidro-izoindol-1-on |
| US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
| US20180134667A1 (en) | 2016-10-14 | 2018-05-17 | TES Pharma S.r.I. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| MX2021005904A (es) | 2018-11-20 | 2021-09-08 | Tes Pharma S R L | Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687147A1 (fr) * | 1992-02-11 | 1993-08-13 | Union Pharma Scient Appl | Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| SI1169312T1 (en) | 1999-03-29 | 2005-02-28 | F. Hoffmann-La Roche Ag | Glucokinase activators |
| DK1280801T3 (da) | 2000-05-03 | 2006-01-23 | Hoffmann La Roche | Hydantoinholdige glucokinaseaktivatorer |
| MXPA02010796A (es) | 2000-05-08 | 2003-03-27 | Hoffmann La Roche | Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa. |
-
2001
- 2001-12-06 US US10/010,978 patent/US6482951B2/en not_active Expired - Fee Related
- 2001-12-07 CA CA2430579A patent/CA2430579C/en not_active Expired - Fee Related
- 2001-12-07 KR KR10-2003-7007869A patent/KR100520651B1/ko not_active IP Right Cessation
- 2001-12-07 DE DE60111570T patent/DE60111570T2/de not_active Expired - Lifetime
- 2001-12-07 CN CNB018206107A patent/CN1247574C/zh not_active Expired - Fee Related
- 2001-12-07 SK SK873-2003A patent/SK8732003A3/sk unknown
- 2001-12-07 ES ES01986857T patent/ES2243578T3/es not_active Expired - Lifetime
- 2001-12-07 PL PL01366006A patent/PL366006A1/xx unknown
- 2001-12-07 NZ NZ526236A patent/NZ526236A/xx unknown
- 2001-12-07 WO PCT/EP2001/014404 patent/WO2002048106A2/en active IP Right Grant
- 2001-12-07 SI SI200130381T patent/SI1349856T1/xx unknown
- 2001-12-07 RS YUP-477/03A patent/RS50933B/sr unknown
- 2001-12-07 AT AT01986857T patent/ATE297922T1/de active
- 2001-12-07 JP JP2002549637A patent/JP4021766B2/ja not_active Expired - Fee Related
- 2001-12-07 MX MXPA03005170A patent/MXPA03005170A/es active IP Right Grant
- 2001-12-07 DK DK01986857T patent/DK1349856T3/da active
- 2001-12-07 RU RU2003120512/04A patent/RU2249590C2/ru not_active IP Right Cessation
- 2001-12-07 AU AU3841502A patent/AU3841502A/xx active Pending
- 2001-12-07 IL IL15626401A patent/IL156264A0/xx unknown
- 2001-12-07 CZ CZ20031882A patent/CZ20031882A3/cs unknown
- 2001-12-07 AU AU2002238415A patent/AU2002238415B2/en not_active Ceased
- 2001-12-07 HU HU0400587A patent/HUP0400587A3/hu unknown
- 2001-12-07 PT PT01986857T patent/PT1349856E/pt unknown
- 2001-12-07 BR BR0116169-5A patent/BR0116169A/pt not_active Application Discontinuation
- 2001-12-07 EP EP01986857A patent/EP1349856B1/en not_active Expired - Lifetime
- 2001-12-10 PA PA20018534601A patent/PA8534601A1/es unknown
- 2001-12-10 EG EG20011316A patent/EG24358A/xx active
- 2001-12-10 TW TW090130510A patent/TWI294876B/zh not_active IP Right Cessation
- 2001-12-11 PE PE2001001234A patent/PE20020593A1/es not_active Application Discontinuation
- 2001-12-11 MY MYPI20015613A patent/MY136741A/en unknown
- 2001-12-12 UY UY27069A patent/UY27069A1/es not_active Application Discontinuation
-
2003
- 2003-06-02 IL IL156264A patent/IL156264A/en not_active IP Right Cessation
- 2003-06-04 HR HR20030450A patent/HRP20030450B1/xx not_active IP Right Cessation
- 2003-06-12 NO NO20032674A patent/NO325810B1/no not_active IP Right Cessation
- 2003-06-12 MA MA27197A patent/MA26973A1/fr unknown
- 2003-06-13 BG BG107903A patent/BG107903A/bg unknown
-
2004
- 2004-08-11 HK HK04106031A patent/HK1063314A1/xx not_active IP Right Cessation
-
2005
- 2005-09-15 CY CY20051101133T patent/CY1105587T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0400587A2 (hu) | Izoindolin-1-on glükokináz aktivátorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0203753A2 (hu) | Transz-olefinszerkezetű glükokináz-aktivátorok, eljárás az előállításukra és alkalmazásuk | |
| NZ514038A (en) | Glucokinase activators | |
| HRP20050287A2 (en) | Indole-3-carboxamides as glucokinase (gk) activators | |
| HUP0202897A2 (hu) | Diaminotiazolok és a vegyületek protein kinázok gátlására való alkalmazása és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0303652A2 (hu) | Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények | |
| ECSP941146A (es) | Derivados de benzofurano | |
| HUP0303258A2 (hu) | N-szubsztituált nem aril-heterociklusos NMDA/NR2B antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0100064A2 (hu) | Amidszármazékot és klórtalonilt tartalmazó, szinergetikus fungicid kombináció és alkalmazása | |
| WO2004055005A8 (en) | Novel compounds having selective inhibiting effect at gsk3 | |
| DK586588A (da) | Terapeutiske heterocycliske forbindelser | |
| HUP0103469A2 (hu) | Szubsztituált oxazol- és tiazolszármazékok hPPAR gamma és hPPAR alfa aktivátor hatással és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0301249A2 (hu) | APO B termelődés gátló benzamid-vegyületek ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| WO2001083478A3 (en) | Hydantoin-containing glucokinase activators | |
| HUP0203403A2 (hu) | Új imidazol-száemazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| PT96096A (pt) | Processo de estabilizacao de uma mistura aquosa de um composto heterociclico de azoto e de preparacao de composicoes estabilizadas com metionina | |
| HUP9803018A2 (hu) | Ciklooxigenáz-2 gátló hatású vegyületek alkalmazása tumorok, tumorral kapcsolatos rendellenességek és cachexia kezelésére alkalmas gyógyszerkészítmények előállítására | |
| MY100665A (en) | 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives. | |
| SE9904421D0 (sv) | New compounds | |
| NZ314406A (en) | Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles | |
| HUP0004342A2 (hu) | (Het)aril-karbonsavamidot és (+)-(2-klór-fenil)-(5-pirimidil)-metanolt tartalmazó szinergetikus fungicid hatóanyagkeverék és alkalmazása | |
| HUP9801155A2 (hu) | Amiloid béta-protein-termelést vagy kiválasztást gátló készítmények | |
| DK1615638T3 (da) | Anvendelse af 7-nitro-2,1,3-benzoxadiazolderivater til behandling af cancer | |
| HUP0400322A2 (hu) | Dibenzo-cikloheptén-származékok, és ezeket tartalmazó gyógyszerkészítmények | |
| AR028606A1 (es) | Nuevos inhibidores de mmp-2/mmp-9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |